Please use this identifier to cite or link to this item:
http://repository.li.mahidol.ac.th/dspace/handle/123456789/14800
Title: | Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major |
Authors: | Dudley J. Pennell John B. Porter Maria Domenica Cappellini Lee Lee Chan Amal El-Beshlawy Yesim Aydinok Hishamshah Ibrahim Chi Kong Li Vip Viprakasit Mohsen S. Elalfy Antonis Kattamis Gillian Smith Dany Habr Gabor Domokos Bernard Roubert Ali Taher Royal Brompton Hospital UCL Universita degli Studi di Milano University of Malaya Medical Centre Cairo University Ege Universitesi Kuala Lumpur Hospital Prince of Wales Hospital Hong Kong Mahidol University Ain Shams University University of Athens Novartis Pharmaceuticals Novartis International AG American University of Beirut |
Keywords: | Medicine |
Issue Date: | 1-Jun-2012 |
Citation: | Haematologica. Vol.97, No.6 (2012), 842-848 |
Abstract: | Background Prospective data on cardiac iron removal are limited beyond one year and longer-term studies are, therefore, important. Design and Methods Seventy-one patients in the EPIC cardiac substudy elected to continue into the 3 rd year, allowing cardiac iron removal to be analyzed over three years. Results Mean deferasirox dose during year 3 was 33.6±9.8 mg/kg per day. Myocardial T2*, assessed by cardiovascular magnetic resonance, significantly increased from 12.0 ms ±39.1% at baseline to 17.1 ms ±62.0% at end of study (P < 0.001), corresponding to a decrease in cardiac iron concentration (based on ad hoc analysis of T2*) from 2.43±1.2 mg Fe/g dry weight (dw) at baseline to 1.80 ±1.4 mg Fe/g dw at end of study (P < 0.001). After three years, 68.1% of patients with baseline T2* 10 to < 20 ms normalized (≥20 ms) and 50.0% of patients with baseline T2* > 5 to < 10 ms improved to 10 to < 20 ms. There was no significant variation in left ventricular ejection fraction over the three years. No deaths occurred and the most common investigator-assessed drugrelated adverse event in year 3 was increased serum creatinine (n=9, 12.7%). Conclusions Three years of deferasirox treatment along with a clinically manageable safety profile significantly reduced cardiac iron overload versus baseline and normalized T2* in 68.1% (32 of 47) of patients with T2* 10 to < 20 ms. © 2012 Ferrata Storti Foundation. |
URI: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84862141974&origin=inward http://repository.li.mahidol.ac.th/dspace/handle/123456789/14800 |
ISSN: | 15928721 03906078 |
Appears in Collections: | Scopus 2011-2015 |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.